184 related articles for article (PubMed ID: 36923304)
21. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
22. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
23. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y; Nakano K; Katayama K; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Imamura R; Yamaguchi R; Imoto S; Shiotsu Y; Nonomura N; Uemura M
Int J Urol; 2022 May; 29(5):462-469. PubMed ID: 35184335
[TBL] [Abstract][Full Text] [Related]
24. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.
Salgia NJ; Bergerot PG; Maia MC; Dizman N; Hsu J; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
Eur Urol; 2020 Oct; 78(4):498-502. PubMed ID: 32828600
[TBL] [Abstract][Full Text] [Related]
25. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
26. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
27. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
28. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
29. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
30. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
33. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma.
Lee CH; Jung SJ; Seo WI; Chung JI; Lee DS; Jeong DH; Jeon Y; Choi I
Int J Immunopathol Pharmacol; 2022; 36():3946320221125588. PubMed ID: 36083857
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
[TBL] [Abstract][Full Text] [Related]
35. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
36. Designing novel immunocombinations in metastatic renal cell carcinoma.
Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
[TBL] [Abstract][Full Text] [Related]
37. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.
Park JJ; Kellezi O; Hamasha R; Ali A; Alva AS
Cancer Treat Res Commun; 2020; 25():100251. PubMed ID: 33310369
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Ravi P; Mantia C; Su C; Sorenson K; Elhag D; Rathi N; Bakouny Z; Agarwal N; Zakharia Y; Costello BA; McKay RR; Narayan V; Alva A; McGregor BA; Gao X; McDermott DF; Choueiri TK
JAMA Oncol; 2020 Oct; 6(10):1606-1610. PubMed ID: 32469396
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Brown LC; Zhu J; Labriola MK; Wu Y; Cheris S; Liu X; Perkinson K; Su Z; McCall S; Huang J; Foo WC; Gupta RT; Armstrong AJ; George DJ; Harrison MR; Zhang T
Clin Genitourin Cancer; 2020 Dec; 18(6):509-513. PubMed ID: 32482566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]